CRO giant inVentiv Health has opened a one-stop shop in the London suburbs, consolidating three of its U.K. operations into one all-encompassing office to better meet European demand.
CRO Novum has opened its latest hub for clinical trials, expanding into Fargo, ND, in an effort to grow the company's footprint and diversify its offerings.
Research outfit SRI International is bolstering its CRO division, spending millions to stretch its capabilities and lure more drug development clients to its Virginia labs.
CRO giant Icon is riding high on another spike in revenue, again upping its full-year expectations after increasing profits by more than 50%.
Swiss CRO Atheris Laboratories has signed a deal with Debiopharm to help develop a peptide cancer drug, optimizing leads for an innovative venom-derived treatment.
WuXi PharmaTech won CLIA certification for its Shanghai genomics lab, making it the first such outfit in China to meet U.S. testing standards.
U.K. contractor DrugDev has purchased software provider CFS Clinical with plans to merge the company's trial management program with its own investigator network.
India's ongoing efforts to tighten clinical trial regulations have stirred controversy among researchers around the globe, and now the world's largest CRO has shuttered one of its facilities in the country, citing a tough regulatory climate.
Germany's Aenova has sealed a deal for contract development and manufacturing outfit Haupt Pharma, a buyout that expands its capabilities and global reach.
Pennsylvania contractor Clinlogix has bought Germany's ikfe CRO, looking to expand its presence in Europe's market for clinical development.
Novella Clinical has snagged its first high-profile partnership since being bought by CRO giant Quintiles, teaming up with biotech Scioderm to manage a mid-stage trial of the company's rare skin disease treatment.
English CRO Cmed is reaching into Boston and San Francisco, growing its U.S. presence and giving it a front-row seat at two hotbeds of biotech activity.
Quintiles is lending its research and analytics expertise to the Muscular Dystrophy Association, signing a deal to develop a massive registry of patient data that could help investigators develop new therapies.
Parexel International has inked a deal to pool its clinical trial data management service with a Japanese provider, teaming up to expand its share of the local market.
Irish CRO Icon is riding the spike in demand for adaptive trial monitoring, unveiling a new service that parses study data and highlights potential safety issues in real time.
Like many top-tier schools, Yale University has a wealth of expertise and capability in clinical research, and now, citing demand for medical device studies, the Ivy League institution has teamed up with a CRO to land more trial contracts.
Catalent has snapped up a Brazilian contract manufacturer, expanding its hold on the global softgel market by growing its presence in Latin America.
Syngene, the CRO arm of Indian biotech giant Biocon, is poised to swell about 20% a year, CEO Kiran Mazumdar-Shaw said, making it the continent's fastest-growing service provider.
Drug developers look to external labs to do all manners of tests, but they can easily get stretched too thin when trying to manage myriad vendors. Covance is kicking off an external lab management offering, promising to save its clients as much as 65% in oversight costs.
After a booming 2012, the CRO industry is likely to grow even further, one analyst projects, riding an increase in biotech funding and drug development successes.